This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Cencora, Inc.
11/4/2026
Thank you, Bennett. Hi, everyone, and thank you for joining Sencora's fiscal 2026 fourth quarter and full year earnings call. I want to begin by thanking our team members. Throughout the fiscal year, their commitment to our purpose and dedication to our customers fueled our performance as we delivered adjusted operating income growth of 14% and adjusted diluted EPS of $17.97, up 12%. Our fiscal 2026 performance demonstrates the strength of our business and the progress we've made with leadership and specialty and a portfolio increasingly aligned to the areas where we can create the greatest long-term value. We enter fiscal 2027 with momentum and greater operational and strategic focus. The outlook reflects our confidence and is aligned with our long-term targets when excluding the businesses and other. This morning, I will focus on two areas, the strategic progress delivered in fiscal 2026 and how our updated operating model will strengthen execution, customer focus, and visibility for investors. I'll begin with the strategic progress delivered in fiscal 2026. Two years ago, We introduced a refined strategy to lead with market leaders, strengthen our position and specialty, and enhance patient access to pharmaceuticals. In fiscal 2026, we advanced each priority, delivered another year of record results, and expanded capabilities that support patient access to innovation in the specialty pharmaceutical market, where growth has been twice that of the broader market over the past five years. Our MSO platform is one important example. In February, we completed our acquisition of One Oncology, expanding our position at one of healthcare's fastest growing areas. Together, One Oncology and Retina Consultants of America deepen our relationships with community-based specialists and strengthen our ability to support pharmaceutical-centric care closer to where patients live. During the fiscal year, We continue to build the MSO platform, including the announced acquisition of iSouth's retina business in March, and most recently, our agreement to acquire a majority interest in American Oncology Network. These additions will expand the capabilities and reach of the platform built to help independent specialty practices thrive, improve patient access to high quality care, and create opportunities to support pharmaceutical companies across the product lifecycle. In fact, at RCA, we participate in the vast majority of retina clinical trials, completing over 40,000 research-related visits annually. And One Oncology has supported more than 130 pharmaceutical partners with their clinical trials to date. As we've invested in the businesses aligned with our pharmaceutical-centric strategy, we've also taken decisive action on businesses that do not align. Concentrating our capital and leadership attention where Sancora is most differentiated. Over the course of the year, we entered into agreements or completed divestitures for all the businesses within other. While these actions can cause near-term financial headwinds, they allow us to direct our resources towards the areas where we can create the greatest value for customers and shareholders over the long term. The same discipline guiding our portfolio informs how we operate. This morning, we introduced an updated operating model aligned with our strategy and the customers we serve. Our pharmaceutical-centric strategy is focused on strengthening our leadership and specialty and delivering greater value across pharmaceutical services. As the needs of manufacturers and providers evolve, we're adapting our organization to better support them while preserving the benefits of Sancora's scale infrastructure, and expertise. I believe this operating model will make SYNCORA more effective in three ways. Enhancing our strategic and operational execution, further elevating the voice of our customers, and providing increased visibility for our shareholders. Informed by our updated operating model, we've created two new reporting segments. Specialty pharmaceutical and provider services brings together our specialty capabilities in an integrated growth platform supporting innovation from pharmaceutical manufacturers to physician providers. Pharmaceutical distribution and services organized around our broad portfolio of customers and the services we provide, while leveraging our scale to deliver sustained growth and strong cash flow generation, powering investments across the enterprise. Now I'll share a bit more about each segment. Starting with specialty pharmaceutical and provider services. We are connecting capabilities across clinical trial logistics, commercialization, specialty distribution, GPO, and practice management to support innovative therapies from development to delivery to patient. That role is becoming more important with specialty biologics now accounting for more than half of all pharmaceutical spending in the United States up 80% in five years. With over 100 new products expected to launch through 2030, oncology illustrates the growing need for specialized clinical logistics, distribution, and provider support as the pipeline expands and therapies become more complex. These are capabilities Sincora has built at scale through focused investments. With specialty logistics operations across more than 50 countries, and multinational 3PL solutions in the United States and Europe. We can support pharmaceutical partners as they bring complex therapies to patients across markets. Our role does not end when a therapy reaches its destination. As more specialty care is delivered in community settings, providers are managing increasing clinical and administrative demands. Through our MSOs, we help independent specialty physicians manage clinical and administrative complexity, expand access to research, and remain focused on patient care. Our agreement to acquire a majority interest in Aon extends the platform through a physician-led network and a longstanding Sencora partner. Bringing these businesses together deepens our relationships with manufacturers and providers while giving investors a clearer view of the growth potential of our specialty platform. Within pharmaceutical distribution and services, our scale provides us with deep understanding of trends across the healthcare ecosystem, which we use to drive differentiated value to customers. We deliver over 100 million packages annually, shipping nearly 5 million units each day, giving our leaders firsthand insight into the needs of manufacturers, providers, pharmacies, and patients. Combining our scale, our sourcing expertise, and customer-centric partnerships with pharmacies and health systems, large and small, we strengthen their operations, support their growth and ensure continued patient access. Two recent customer events illustrate how the perspective shape our priorities. At our Health Systems National Summit, health systems leaders discussed how connecting pharmacy, supply chain, technology and care delivery leads to better decisions for patients and their organizations. These are all areas where our accelerate pharmacy solutions help our health systems customers. At ThoughtSpot, our annual trade show for good neighbor independent pharmacies, we came together with more than 3,000 attendees, introducing novel solutions, including AI-powered tools designed to help pharmacies run more efficiently, free up time for patient care, and create new growth opportunities. At both our Health Systems National Summit and ThoughtSpot, I heard customers emphasize that specialty is becoming a larger and more complex part of patient care, reinforcing the importance of specialty growth and solutions across both reporting segments. The scale of this opportunity is increasingly visible in our results. We expect specialty distribution revenue to reach approximately $100 billion in fiscal 2027. Combined with our broader manufacturer and provider capabilities, this makes specialty a central driver of Sancora's long-term growth. In summary, we exit fiscal 2026 with record results in a stronger platform for growth, supported by our scale, specialty capabilities, and an operating model aligned to how we create value. With that, I'll turn the call over to Eva to discuss our fourth quarter and fiscal 2026 results as well as our fiscal 2027 guidance. Eva.
Thanks, Bob. Good morning, everyone. As Bob highlighted and we shared in our press release this morning, we have introduced a new organizational and financial reporting structure designed to strengthen our execution and provide additional performance visibility to our shareholders. Through our new segments, we will highlight the significant opportunity we have to utilize our end-to-end specialty capabilities to deliver value up and downstream while driving sustainable growth powered by our scale and efficient pharmaceutical distribution foundation. In addition to reiterating SYNCORA's long-term growth algorithm of 7% to 10% operating income growth and 10% to 14% EPS growth, we are introducing targets for our new segment. For the pharmaceutical distribution and services segment, we expect long-term operating income to grow in the mid-single digits. And for the specialty pharmaceutical and provider services segment, we expect long-term operating income growth in the mid-teens. Now, I'll provide an overview of our fiscal 2026 fourth quarter and full-year results and our fiscal 2027 financial guidance. unless otherwise stated, my remarks will focus on adjusted non-GAAP financial results. For further discussion of our GAAP results, please refer to our earnings press release and presentation. Beginning with fourth quarter, consolidated revenue was $88.4 billion, up 6%, driven by growth in both reportable segments and in other. which I'll describe in more detail when discussing segment level results. Consolidated adjusted gross profit was $3.6 billion, up 23% primarily due to growth in the U.S. healthcare solution segment. Consolidated adjusted gross margin expanded by 57 basis points to 4.04%. largely due to our acquisition of One Oncology in February. Consolidated adjusted operating expenses were $2.3 billion, an increase of 23%, again, largely driven by the impact of the February 2026 acquisition of One Oncology. Excluding both One Oncology and RCA, operating expense growth was less than 3%. as we lapped an easier expense comparison. Consolidated adjusted operating income was $1.2 billion, an increase of 22% compared to the prior year quarter, with another quarter of double digit growth across both reportable segments and other. Moving now to below the line items, net interest expense was $136 million, an increase of $58 million compared to the prior year quarter, primarily due to debt raised to finance the One Oncology acquisition. Our effective tax rate was 20.2% compared to 20.6% in the prior year quarter. Finally, diluted share count was 191.7 million shares a 1.8% decrease compared to the prior year quarter, largely due to the $1 billion of opportunistic share repurchases we completed in the June quarter. Taken together, this resulted in adjusted diluted earnings per share of $4.66, an increase of 21%. Turning to our segment results for the fourth quarter, U.S. Healthcare Solutions revenue with $78.3 billion, an increase of 5%. Strength in specialty sales to health systems and physician practices and continued growth in GLP-1, which increased by $2.8 billion year over year, drove the growth. The growth was partially offset by manufacturer list price reductions that represented a $2.8 billion headwind to revenue growth, as well as lower sales to our large mail order customer, consistent with the past two quarters. U.S. healthcare solution segment operating income was $998 million, up 22%, representing our strongest growth quarter of the fiscal year. This was driven by continued momentum in specialty across both health systems and physician practices, the contribution from One Oncology, and focused execution across our other pharmaceutical distribution businesses. The quarter also benefited from an easier expense comparison. Turning now to our international healthcare solution segment, revenue was $7.8 billion, up 5%, driven by growth in all business units. International Healthcare Solutions operating income was $152 million, up 16% on an as reported basis and up 19% on a constant currency basis. In the quarter, our Canadian business delivered excellent performance driven by high program win rates. Our global specialty logistics and 3PL business continue to drive strong performance with double-digit operating income growth. As Bob mentioned, we have been investing in these businesses to capitalize on the increasing complexity in the innovation pipeline and have been winning in these areas. Moving to other, which reflects the businesses for which we are pursuing strategic alternatives, revenue in other was $2.3 billion, up 10%, largely due to growth at Pro Pharma and MWI Animal Health. Operating income was $101 million, up 36% due to operating income growth at MWI Animal Health, also including the benefit from being accounted for as health for sale. This completes the review of our fourth quarter results. now turn to a discussion of our full-year fiscal 2026 results. Our consolidated revenue was $337 billion, up 5%, driven by U.S. healthcare solution segment growth of 5% and international healthcare solution segment growth of 8%. Consolidated operating income was $4.8 billion, an increase of 14% driven by growth in both reportable segments. In the U.S. Healthcare Solutions segment, we benefited from strength in specialty volumes and our strategic investments in MSOs. In the fiscal year, MSOs represented approximately 10% of enterprise operating income. When excluding the impact of our two large MSO acquisitions, and the loss of an oncology customer, our core U.S. segment growth was about 13%, nicely ahead of our long-term growth algorithm. In the international healthcare solution segment, we were pleased with the businesses' return to growth this fiscal year, driven by operational improvements at our global specialty logistics business and increased demand. Finally, as it relates to free cash flow, and our balance sheet, during the fiscal year we generated $3.8 billion of adjusted free cash flow, stronger than our guidance due to a combination of year-end stronger volume, mix and timing. We ended the year with a cash balance of $4.9 billion. Our strong free cash flow generation gives us significant flexibility to pursue our balanced capital deployment strategy while maintaining our strong investment grade credit ratings. During the fiscal year, we were pleased to return $1.5 billion to shareholders through a combination of opportunistic share repurchases and our dividend. And this morning, we announced a 10% increase to our quarterly dividend. are 22nd consecutive increase. Turning now to our fiscal 2027 expectations, there are a few items I'll highlight before we get into the details of our guidance. First, our guidance excludes the acquisitions of iSouth Retina Business and American Oncology Network, which we will incorporate upon the close of each transaction. Second, Our guidance contemplates a mid-fiscal year close of the MWI merger with Covetris. The operating income headwind is expected to be partially offset by two below-the-line income items associated with the transaction, which would be approximately $40 million in the second half of fiscal 2027. This contribution is expected to bring are other income loss line to approximately $90 million compared to the approximate $26 million in fiscal 2026. Third, as we announced this morning, we reached an agreement to sell our equity stake in Pro Pharma with the close expected to occur in our fiscal first quarter. Given the nature of our ownership, We consolidate the full pro-pharma income statement and eliminate our non-controlling interest in the company, making it a much less meaningful contributor at the EPS level, which is fully reflected in our revenue operating income and EPS guidance. With that as context, we expect adjusted diluted EPS to be in the range of $19.40 to $19.75, reflecting headline growth of 8% to 10%. Excluding the assumed $0.35 impact of the mid-fiscal year merger of MWI and Covetris, adjusted EPS growth would be 10% to 12%. We expect consolidated revenue growth to be in the range of 3% to 5%. Operating income growth is expected to be in the range of 4% to 6%. The businesses and other are expected to have an approximate 5 percentage point negative impact on our growth, largely due to the assumed mid-fiscal year closing of the merger of MWI and Covetris. Excluding the businesses and other, our guidance would reflect adjusted operating growth of 8.5% to 11% ahead of our long-term targets. We expect interest expense to be in the range of $490 million to $510 million, reflecting debt we raised in connection with the One Oncology transaction. We expect to pay $1 billion on the remaining One Oncology term loan at the end of fiscal year 2027. We expect our effective tax rate to be approximately 20% for fiscal 2027. We expect full-year diluted average shares outstanding to be approximately 190 million shares. This reflects the annualization of opportunistic share repurchases we completed in the third quarter of fiscal 2026 and an expectation of an additional 1.25 billion dollars in repurchases in fiscal 2027. We expect capital expenditures to be approximately 1 billion dollars in fiscal 2027, which reflects continued investments in our supply chain, digital and MSO infrastructure. We expect adjusted free cash flow to be approximately 3.5 billion dollars. That completes the review of our consolidated fiscal 2027 expectations. I'll now turn to segment level expectations. In the pharmaceutical distribution and services segment, we expect revenue growth to be in the range of 4% to 6%. We expect pharmaceutical distribution and services segment operating income growth to be 2% to 4%. which includes the wraparound impact of a certain customer's volume shift as previously disclosed. The segment operating income growth expectations also include an approximate $20 million headwind related to our European distribution business resulting from the strengthening of the U.S. dollar. Moving now to the specialty pharmaceutical and provider services segment, We expect revenue growth to be in the range of 9% to 14% and segment operating income growth to be in the range of 18% to 21% ahead of our segment level long-term operating income growth expectations of mid-teens. Reflecting the wraparound contribution from the One Oncology acquisition that we closed in February 2026. Moving now to other, we expect revenue in other to be approximately $3.5 billion and operating income in other to be approximately $200 million. We are pleased with the significant progress we have made to simplify our portfolio, allowing us to better capitalize on growth opportunities aligned with our pharmaceutical-centric strategy. Before turning to my closing remarks, As you think about quarterly cadence, we expect adjusted diluted EPS in our first quarter to be approximately $4.55. In closing, fiscal 2026 marked a year of significant progress on our strategy as we delivered strong financial performance. As we look to fiscal 2027 and beyond, we are well positioned to deliver on our long-term targets and drive sustainable shareholder value creation supported by our differentiated footprint in the high growth specialty market, scaled and efficient foundation in pharmaceutical distribution and strong free cash flows. I'll turn the call back to Bob for some closing remarks before moving to Q&A. Bob?
Thank you, Eva. Our fiscal 2027 guidance reflects our confidence in the strength of the business and our team, our strategy, and our ability to deliver sustainable growth and long-term value for customers and shareholders. With that, we'll open the call for questions. Operator?
You're reading a preview of the COR Q4 2026 earnings call.
Free account.